Inhibition of Type-5 Phosphodiesterase: Promising Therapy for Pulmonary Hypertension

Internal Medicine - Japan
doi 10.2169/internalmedicine.43.891
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japanese Society of Internal Medicine

Related search

Phosphodiesterase Type 5 Inhibitors in the Treatment of Pulmonary Arterial Hypertension

Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology
2010English

Soluble Guanylate Cyclase Stimulators and Phosphodiesterase-5 Inhibitors in Therapy of Some Groups of Pulmonary Hypertension

Pulmonologiya
PulmonaryRespiratory Medicine
2018English

Phosphodiesterase-5 Inhibition in Heart Failure With Preserved Ejection Fraction: Trading Therapy for Prevention

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2017English

Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease

Circulation
Cardiovascular MedicinePhysiologyCardiology
2003English

Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects With Overt Diabetic Nephropathy

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2016English

Survival of Japanese Patients With Pulmonary Arterial Hypertension After the Introduction of Endothelin Receptor Antagonists and/or Phosphodiesterase Type-5 Inhibitors

Internal Medicine
Internal MedicineMedicine
2012English

Therapy for Primary Pulmonary Hypertension

Canadian Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2003English

AB030. Evolution of Phosphodiesterase Type 5 Inhibitors

Translational Andrology and Urology
Reproductive MedicineUrology
2016English

Tadalafil Therapy for Pulmonary Arterial Hypertension

Circulation
Cardiovascular MedicinePhysiologyCardiology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy